|
Kuwait Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Kuwait Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Kuwait.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Kuwaiti pharmaceutical and healthcare industry.
Competitive intelligence, Kuwaiti pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Kuwaiti market.
The Kuwait Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Kuwait Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Kuwaiti pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Kuwait to test other views – a key input for successful budgeting and strategic business planning in the Kuwaiti pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Kuwaiti Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Kuwait.
- Exploit The Latest Competitive Kuwaiti Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Kuwait.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Kuwait Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Kuwait Pharmaceuticals And Healthcare Industry SWOT |
| Kuwait Political SWOT |
| Kuwait Economic SWOT |
| Kuwait Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Regional Business Environment Ratings |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Kuwait – Market Summary |
| Regulatory Regime |
| Foreign Direct Investment Regulations |
| Intellectual Property Regime |
| IP Shortcomings |
| Pricing And Reimbursement Regime |
| Public Procurement Of Medicines |
| Regional Harmonisation |
| Free Trade Agreements |
Chapter - Industry Developments |
| Epidemiology |
| Healthcare Sector |
| Primary Care |
| Secondary Care |
| Recent Public Health Developments |
| Healthcare Insurance |
| Healthcare Reforms |
| Regional Developments |
| International Collaboration |
| Pharmaceutical Sector |
| Research And Development |
| Biotechnology Sector |
| Medical Devices |
| Table: Diverse Potential For Product Launches: New Products For 2009 |
Chapter - Industry Forecast Scenario |
| Overall Market Forecasts |
| Table: Kuwait – Drug Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Industry |
| Table: Kuwait – Health Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Macroeconomic |
| Table: Kuwait – Economic Activity, 2006-2013 |
| Prescription Drug Market Forecast |
| Table: Kuwait - Prescription Market Indicators, Historical Data And Forecasts (KWDmn unless otherwise stated) |
| Patented Drug Market Forecast |
| Table: Kuwait – Patented Market Indicators, Historical Data And Forecasts |
| Generics Market Forecast |
| Table: Kuwait – Generics Market Indicators, Historical Data And Forecasts |
| OTC Market Forecast |
| Table: Kuwait – OTC Market Indicators, Historical Data And Forecasts (KWDmn unless otherwise stated) |
| Export/Import Market Forecasts |
| Table: Kuwait – Pharmaceutical Trade Indicators, Historical Data And Forecasts (US$mn unless otherwise stated) |
| Table: India's Export Of Pharmaceutical Products To GCC Countries (US$mn) |
| Medical Devices Forecast |
| Table: Kuwait's Medical Devices Market, 2003-2013 (US$mn unless otherwise stated) |
| Other Healthcare Data |
| Table: Kuwait – Other Healthcare Indicators, Historical Data And Forecasts, 2003-2013 |
| Key Risks To BMI Forecasts |
Chapter - Competitive Landscape |
| Company Profiles |
| Multinationals |
| Novartis |
| Sanofi-Aventis |
| Pfizer |
| GlaxoSmithKline |
| Merck & Co |
| Johnson & Johnson |
| Indigenous Players |
| Advanced Technology Company |
| Bader Sultan & Bros |
| Safwan Trading And Contracting Company |
Chapter - Country Snapshot: Kuwait Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 1997-2006 |
| Table: Consumer Expenditure, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Kuwait Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Kuwaiti pharmaceutical market – now slipping to fifth place from third out of the 17 regional markets surveyed in the Middle East and Africa (MEA) Business Environment Ranking matrix - will record unspectacular growth in the next five years. The rate of this growth will also be offset by inflation and the government’s cost-containment policy, focusing on generic reimbursement. Overall, the market is likely to reach around US$508mn at consumer prices by 2013, up from US$377mn in 2008, equal to US$131 per capita, with both figures small in global terms. The market will post a compound annual growth rate (CAGR) of 5.38% in nominal terms, or a slightly higher 6.15% in US dollar terms, While prescription medicines will continue to dominate a lion’s share of the overall market, the recent regionwide regulatory changes – notably the recent attempts to draft legislation on alternative and traditional medicines - will stimulate the development of the over-the-counter (OTC) segment, although it will still remain small in absolute term.
Other segments of the healthcare market are also severely limited by the small size of Kuwait's population. Nevertheless, BMI expects the medical device sector to grow over the coming years, supported by government's strategy to continue undertaking reforms in the healthcare sector as well as partially by the efforts of Kuwaiti distributers seeking new suppliers. We estimated that the market was worth US$78.7mn in 2008, with the figure forecast to top US$98.1mn in 2013, growing at a CAGR of some 3.74% in nominal terms. Given that imports meet virtually all of the demand, foreign companies and their local distributors will be the beneficiaries of this trend. The recent purchase by the Kuwaiti government of nuclear radiation protection drugs, amid concerns of a fallout of a possible conflict between Israel/the US and Iran, or a meltdown of the soon-to-be-operational Iranian Bushehr nuclear power plant, may also lead to purchases of radiation detection and similar medical devices.
In the meantime, the Kuwaiti government is under increasing pressure to deal with the economic turmoil, and, as parliament becomes even angrier with the government, this could lead the latter to make some potentially damaging decisions. There is also a risk of early elections: new polls are not due until 2012, but Kuwait has a history of dissolving governments. While we would not expect this to result in any meaningful change of government - parliament is already dominated by the opposition and the royal family is not about to be overthrown - it could destabilise the country, delay reforms, deter investors and lead to even further fiscal laxity. Nevertheless, although Kuwait faces substantial structural challenges over the long-term, the energy sector will continue to grow in real terms to 2018, keeping the government in surplus.
|
Kuwait Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |